Gluxit Trio: A Comprehensive Diabetes Treatment

Gluxit Trio is a once-daily oral tablet containing a combination of Dapagliflozin, Metformin, and Sitagliptin, prescribed to manage type 2 diabetes. This carefully balanced dosage offers a comprehensive approach for improved glycemic control.

Dapagliflozin (5mg): A Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor that promotes glucose excretion in the kidneys, reducing blood sugar levels.

Metformin (1000mg): An insulin-sensitizing medication that improves cellular uptake of glucose and reduces hepatic glucose production.

Sitagliptin (50mg): A dipeptidyl peptidase-4 (DPP-4) inhibitor that boosts incretin hormone levels, stimulating insulin release in response to glucose.

Gluxit Trio is specifically designed for patients with type 2 diabetes who struggle with blood sugar management and require a multifaceted solution. It offers improved glycemic control by reducing fasting and postprandial glucose levels, while minimizing adverse effects commonly associated with monotherapy. Always consult your healthcare provider for personalized treatment recommendations.

Important Note: This information is for informational purposes only and should not be considered medical advice. Consult a healthcare professional before starting or changing any medication regimen.